IP Library Granted Patent US 9,320,775
Granted Patent B2
US 9,320,775 · App. 12/433,047 · Granted Apr 26, 2016

Use of nucleic acids with reduced pressure therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,320,775
App. No.
12/433,047
Granted
Apr 26, 2016
Kind
B2
Abstract

Provided is a method of treating a wound site. Also provided is a system for treating a wound site. Additionally provided is the use of reduced pressure and a nucleic acid that promotes wound healing for treatment of a wound site. Further provided is the use of a nucleic acid that promotes wound healing for the manufacture of a medicament for treating a wound site that is undergoing reduced pressure treatment.

Claims (6)

1. A method of treating a wound site in dermal tissue, the method comprising:

positioning at the wound site a reticulated open cell foam dressing having a plurality of flow channels, wherein the dressing is fluidly connected to a reduced pressure source; applying a nucleic acid to the dressing, wherein the nucleic acid is operably linked to a control element that directs expression of the nucleic acid inside a cell, and encodes a transcription factor selected from the group consisting of hypoxia-inducible factor 1-alpha (HIF-1α), homeobox protein HoxD3, and E-26 transformation-specific factor Net, promoting wound healing to the wound site; and applying reduced pressure from the reduced pressure source through the plurality of flow channels to the wound site for promoting wound healing, wherein the applying of the nucleic acid to the dressing is performed using a nucleic acid source fluidly connected to the dressing, and the method comprises alternating between the applying of reduced pressure and the applying the nucleic acid.

2. The method of claim 1 wherein the nucleic acid is applied to the dressing before positioning the dressing at the wound site.

3. The method of claim 1 , wherein the dressing is a reticulated open cell polyurethane foam.

4. The method of claim 1 , wherein the transcription factor is HIF-1α.

5. The method of claim 1 , wherein the transcription factor is homeobox protein HoxD3.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066445/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064790/0085 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2016
From: MCNULTY, AMY; KIESWETTER, KRISTINE
To: KCI LICENSING, INC.
Reel/Frame 038019/0219 →